2023
Safety Outcomes of Antiplatelet Therapy During Endovascular Treatment of Tandem Lesions in Acute Ischemic Stroke Patients
Farooqui M, Divani A, Galecio-Castillo M, Hassan A, Jumaa M, Ribo M, Abraham M, Petersen N, Fifi J, Guerrero W, Malik A, Siegler J, Nguyen T, Sheth S, Yoo A, Linares G, Janjua N, Quispe-Orozco D, Ikram A, Tekle W, Zaidi S, Zevallos C, Rizzo F, Barkley T, De Leacy R, Khalife J, Abdalkader M, Salazar-Marioni S, Soomro J, Gordon W, Rodriguez-Calienes A, Vivanco-Suarez J, Turabova C, Mokin M, Yavagal D, Ortega-Gutierrez S. Safety Outcomes of Antiplatelet Therapy During Endovascular Treatment of Tandem Lesions in Acute Ischemic Stroke Patients. Translational Stroke Research 2023, 1-11. PMID: 38017258, PMCID: PMC11271812, DOI: 10.1007/s12975-023-01214-9.Peer-Reviewed Original ResearchSymptomatic intracranial hemorrhageEndovascular therapyIn-stent thrombosisTandem lesionsAnterior circulation tandem lesionsRate of symptomatic hemorrhageFavorable functional statusTreatment of tandem lesionsRisk of hemorrhageAcute ischemic stroke patientsNo significant associationExcellent reperfusionIschemic stroke patientsSymptomatic hemorrhageMRS 0Intracranial hemorrhageAntiplatelet strategiesEndovascular treatmentMulticenter studyAntiplatelet therapyAntiplatelet medicationsAntiplatelet regimensMTICI 2c/3Carotid stentingPrimary outcomeAntithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry
Murthy S, Zhang C, Shah S, Schwamm L, Fonarow G, Smith E, Bhatt D, Ziai W, Kamel H, Sheth K. Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry. Stroke 2023, 54: 2972-2980. PMID: 37942641, PMCID: PMC10842167, DOI: 10.1161/strokeaha.123.043194.Peer-Reviewed Original ResearchConceptsIschemic vascular diseaseProportion of patientsGuidelines-Stroke registryLipid-lowering therapyIntracerebral hemorrhageVascular diseaseStatin therapyAnticoagulation therapyCardiovascular eventsAtrial fibrillationFuture major cardiovascular eventsLower admission National InstitutesPrevious lipid-lowering therapyAdmission National InstitutesFavorable discharge outcomeIschemic cardiovascular eventsHealth Stroke ScaleMajor cardiovascular eventsLipid-lowering medicationsCross-sectional studyMultiple logistic regressionLogistic regression analysisAntiplatelet medicationsAntiplatelet therapyStatin medication
2020
Adherence to Guideline‐Recommended Therapy—Including Supervised Exercise Therapy Referral—Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry
Saxon JT, Safley DM, Mena‐Hurtado C, Heyligers J, Fitridge R, Shishehbor M, Spertus JA, Gosch K, Patel MR, Smolderen KG. Adherence to Guideline‐Recommended Therapy—Including Supervised Exercise Therapy Referral—Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. Journal Of The American Heart Association 2020, 9: e012541. PMID: 31973609, PMCID: PMC7033887, DOI: 10.1161/jaha.119.012541.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmbulatory Care FacilitiesAustraliaCardiovascular AgentsExercise TherapyFemaleGuideline AdherenceHealthcare DisparitiesHumansMaleMiddle AgedNetherlandsPeripheral Arterial DiseasePractice Guidelines as TopicPractice Patterns, Physicians'Prospective StudiesQuality Indicators, Health CareReferral and ConsultationRegistriesUnited StatesConceptsSupervised exercise therapyPeripheral artery diseaseGuideline-recommended therapiesMedian odds ratioPORTRAIT registryAntiplatelet medicationsPAD symptomsOdds ratioSpecialty clinicSpecialty care facilityEvidence-based careCessation counselingExercise therapyCurrent smokersArtery diseaseCare facilitiesPatientsTherapy/counselingUS sitesReferralTherapyStatinsProcedural databaseQuality measuresMedications
2019
Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes
Murthy SB, Biffi A, Falcone GJ, Sansing LH, Torres Lopez V, Navi BB, Roh DJ, Mandava P, Hanley DF, Ziai WC, Kamel H, Rosand J, Sheth KN, Butcher K, Davis S, Gregson B, Lees K, Lyden P, Mayer S, Muir K, Steiner T. Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes. Stroke 2019, 50: 3057-3063. PMID: 31895618, PMCID: PMC6941441, DOI: 10.1161/strokeaha.119.025972.Peer-Reviewed Original ResearchConceptsAntiplatelet therapyIntracerebral hemorrhageFunctional outcomeHematoma locationCause mortalityMajor disabilityVirtual International Stroke Trials Archive databaseCox proportional regression analysisConclusions Antiplatelet therapyRecurrent intracerebral hemorrhageProportional regression analysisPoor functional outcomeRandomized clinical trialsSpontaneous intracerebral hemorrhagePaucity of dataAntiplatelet medicationsStroke RegistryThromboembolic riskHazard ratioMulticenter cohortPrimary outcomeMedian timeICH patientsClinical trialsMeta-analyzed dataPhysician Practice Patterns for Performing Thoracentesis in Patients Taking Anticoagulant Medications
DeBiasi EM, Murphy TE, Araujo KLB, Pisani MA, Puchalski JT. Physician Practice Patterns for Performing Thoracentesis in Patients Taking Anticoagulant Medications. Journal Of Bronchology & Interventional Pulmonology 2019, 27: 42-49. PMID: 31436608, PMCID: PMC6923589, DOI: 10.1097/lbr.0000000000000614.Peer-Reviewed Original ResearchConceptsPractice patternsDirect oral anticoagulant useLow molecular weight heparinSafety of thoracentesisHigh bleeding riskOral anticoagulant useDirect oral anticoagulantsMolecular weight heparinAmerican Thoracic SocietyPhysician practice patternsPractices of physiciansAcademic medical centerAntiplatelet medicationsBleeding riskOral anticoagulantsAnticoagulant medicationAnticoagulant useEmail distribution listsProphylactic dosesWeight heparinThoracic SocietyGeneral pulmonologistsMedical CenterInterventional pulmonologistsThoracentesis
2013
Perioperative management of antiplatelet therapy
Oprea AD, Popescu WM. Perioperative management of antiplatelet therapy. British Journal Of Anaesthesia 2013, 111: i3-i17. PMID: 24335397, DOI: 10.1093/bja/aet402.Peer-Reviewed Original ResearchConceptsCardiovascular thrombotic eventsAntiplatelet agentsAntiplatelet medicationsThrombotic eventsPerioperative antiplatelet managementFirst-line therapyPreferred therapeutic strategyNovel antiplatelet drugsRisk stratification analysesDifferent pharmacological propertiesAntiplatelet therapyCardiovascular eventsPerioperative managementSurgical bleedingAntiplatelet drugsAntiplatelet managementTherapeutic pathwaysTherapeutic strategiesStratification analysisInterventional proceduresPerioperative teamPharmacokinetic propertiesPharmacological propertiesMajor causeMedications
2011
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial
Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal 2011, 161: 298-306.e1. PMID: 21315212, DOI: 10.1016/j.ahj.2010.10.035.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsGP IIb/IIIa inhibitorsAcute coronary syndromeBivalirudin monotherapyMajor bleedingCoronary syndromePlatelet countClinical consequencesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsPredictors of mortalityAcquired thrombocytopeniaACUITY trialAcute CatheterizationAntiplatelet medicationsAntithrombotic therapyIschemic complicationsAnticoagulant regimenIndependent predictorsStrategy trialThrombocytopeniaPatientsMultivariate analysisMonotherapyLess decline
2010
Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients
Lichtman JH, Naert L, Allen NB, Watanabe E, Jones SB, Barry LC, Bravata DM, Goldstein LB. Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients. Circulation Cardiovascular Quality And Outcomes 2010, 4: 30-38. PMID: 21098780, PMCID: PMC3073519, DOI: 10.1161/circoutcomes.109.850883.Peer-Reviewed Original ResearchConceptsDeep vein thrombosis prophylaxisElderly ischemic stroke patientsIschemic stroke patientsThrombosis prophylaxisAntithrombotic medicationSkilled nursing facilitiesEligible patientsAntithrombotic therapyIschemic strokeAtrial fibrillationStroke patientsNursing facilitiesPatients ages 85 yearsSecondary stroke preventionAge 85 yearsRates of receiptLow treatment ratesRate of treatmentAntiplatelet medicationsStroke preventionEffect of agePatient agePatient characteristicsAntiplatelet drugsMedicare fee
2009
Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R. Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. Journal Of The American College Of Cardiology 2009, 54: 1293-1302. PMID: 19778672, DOI: 10.1016/j.jacc.2009.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAge FactorsAgedAngioplasty, Balloon, CoronaryAnticoagulantsClopidogrelCoronary Artery BypassFemaleGastrointestinal HemorrhageHeparinHirudinsHumansIncidenceIschemiaLength of StayMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk AssessmentSex FactorsStentsThrombosisTiclopidineConceptsAcute coronary syndromeGastrointestinal bleedingACUITY trialComposite ischemiaCardiac mortalityCause mortalityCoronary syndromeHigh-risk acute coronary syndromesStudy drug administrationOpen-label usePotential hemorrhagic complicationsST-segment deviationAntiplatelet medicationsBaseline anemiaHemorrhagic complicationsIschemic complicationsIndependent predictorsClinical outcomesMultivariable analysisStent thrombosisMyocardial infarctionSerious conditionPatientsDrug AdministrationOlder agePrior antiplatelet use does not affect hemorrhage growth or outcome after ICHSYMBOL
Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICHSYMBOL. Neurology 2009, 72: 1397-1402. PMID: 19129506, PMCID: PMC2677505, DOI: 10.1212/01.wnl.0000342709.31341.88.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrainBrain EdemaCausalityCerebral HemorrhageDisease ProgressionDrug-Related Side Effects and Adverse ReactionsFemaleHumansIatrogenic DiseaseImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedOutcome Assessment, Health CarePlatelet Aggregation InhibitorsProspective StudiesTomography, X-Ray ComputedTreatment OutcomeConceptsAntiplatelet medication useAntiplatelet medicationsIntracerebral hemorrhageSpontaneous intracerebral hemorrhageHemorrhage expansionMedication useClinical outcomesICH onsetHemorrhage growthTime of ICHVolume of ICHInitial ICH volumeIntracerebral hemorrhage onsetPrior antiplatelet usePlacebo-controlled trialRecent clinical trialsAssociation of useGrowth of ICHAntiplatelet useEdema growthOral anticoagulationRankin scorePlacebo armCerebral hemorrhageMultivariable analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply